Zaccariotto Eva, Cachón-González María Begoña, Wang Bing, Lim Sungtaek, Hirth Bradford, Park Hyejung, Fezoui Malika, Sardi S Pablo, Mason Paul, Barker Robert H, Cox Timothy M
Department of Medicine, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Biomed Pharmacother. 2022 May;149:112808. doi: 10.1016/j.biopha.2022.112808. Epub 2022 Mar 12.
Krabbe disease is a rare, inherited neurodegenerative disease due to impaired lysosomal β-galactosylceramidase (GALC) activity and formation of neurotoxic β-galactosylsphingosine ('psychosine'). We investigated substrate reduction therapy with a novel brain-penetrant inhibitor of galactosylceramide biosynthesis, RA 5557, in twitcher mice that lack GALC activity and model Krabbe disease. This thienopyridine derivative selectively inhibits uridine diphosphate-galactose glycosyltransferase 8 (UGT8), the final step in the generation of galactosylceramides which are precursors of sulphatide and, in the pathological lysosome, the immediate source of psychosine. Administration of RA 5557, reduced pathologically elevated psychosine concentrations (72-86%) in the midbrain and cerebral cortex in twitcher mice: the inhibitor decreased galactosylceramides by about 70% in midbrain and cerebral cortex in mutant and wild type animals. Exposure to the inhibitor significantly decreased several characteristic inflammatory response markers without causing apparent toxicity to myelin-producing cells in wild type and mutant mice; transcript abundance of oligodendrocyte markers MBP (myelin basic protein) and murine UGT8 was unchanged. Administration of the inhibitor before conception and during several breeding cycles to mice did not impair fertility and gave rise to healthy offspring. Nevertheless, given the unchanged lifespan, it appears that GALC has critical functions in the nervous system beyond the hydrolysis of galactosylceramide and galactosylsphingosine. Our findings support further therapeutic exploration of orally active UGT8 inhibitors in Krabbe disease and related galactosphingolipid disorders. The potent thienopyridine derivative with effective target engagement here studied appears to have an acceptable safety profile in vivo; judicious dose optimization will be needed to ensure efficacious clinical translation.
克拉伯病是一种罕见的遗传性神经退行性疾病,由于溶酶体β-半乳糖神经酰胺酶(GALC)活性受损以及神经毒性β-半乳糖神经鞘氨醇(“精神鞘氨醇”)的形成所致。我们在缺乏GALC活性并模拟克拉伯病的震颤小鼠中,研究了用一种新型的可穿透大脑的半乳糖神经酰胺生物合成抑制剂RA 5557进行底物减少疗法。这种噻吩并吡啶衍生物选择性抑制尿苷二磷酸-半乳糖糖基转移酶8(UGT8),而UGT8是半乳糖神经酰胺生成的最后一步,半乳糖神经酰胺是硫脂的前体,在病理性溶酶体中则是精神鞘氨醇的直接来源。给予RA 5557可降低震颤小鼠中脑和大脑皮质中病理性升高的精神鞘氨醇浓度(72 - 86%):该抑制剂使突变型和野生型动物中脑和大脑皮质中的半乳糖神经酰胺减少约70%。暴露于该抑制剂可显著降低几种特征性炎症反应标志物,而不会对野生型和突变型小鼠中产生髓磷脂的细胞造成明显毒性;少突胶质细胞标志物髓磷脂碱性蛋白(MBP)和小鼠UGT8的转录丰度未改变。在受孕前及几个繁殖周期中给小鼠施用该抑制剂不会损害生育能力,并能产生健康的后代。然而,鉴于寿命未变,似乎GALC在神经系统中除了对半乳糖神经酰胺和半乳糖神经鞘氨醇的水解作用外,还具有关键功能。我们的研究结果支持在克拉伯病及相关半乳糖鞘脂疾病中进一步探索口服活性UGT8抑制剂的治疗作用。本文研究的具有有效靶点作用的强效噻吩并吡啶衍生物在体内似乎具有可接受的安全性;需要明智地优化剂量以确保有效的临床转化。